质量源于设计--医药产品开发的新技术

Anwar Khan , Kamran Javed Naquvi , Md Faheem Haider , Mohsin Ali Khan
{"title":"质量源于设计--医药产品开发的新技术","authors":"Anwar Khan ,&nbsp;Kamran Javed Naquvi ,&nbsp;Md Faheem Haider ,&nbsp;Mohsin Ali Khan","doi":"10.1016/j.ipha.2023.10.004","DOIUrl":null,"url":null,"abstract":"<div><p>Regulatory bodies are nowadays concerned with pharmaceutical drug products' safety, efficacy, and quality. Quality is the priority of all regulatory bodies, it is a high priority for the triple P factor (patient, pharmacist, and physician). It links pharmaceutical industries and regulatory authorities for designing, manufacturing, and consistently delivering safe and efficient products.</p><p>It mainly focuses on fabricating and designing formulations and manufacturing processes to ensure predefined product quality. It is based on the ICH Guidelines Q8 for pharmaceutical development, Q9 for quality risk management, and Q10 for pharmaceutical quality systems. Some of the important effective elements of QbD are to define the target profile that what is the requirement of the pharmacist, physician, and patient (TPP-QTPP) then measuring the criticality for achieving that target (CQA) and analyzing the risk assessment of variables associated with materials and controlling processes to produce consistent quality over time. The objective of this review is to discuss the concept of Quality by Design and describe its application in pharmaceutical product development.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 122-129"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000953/pdfft?md5=f841cf29030eede750e751b2b6ca7a7b&pid=1-s2.0-S2949866X23000953-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Quality by design- newer technique for pharmaceutical product development\",\"authors\":\"Anwar Khan ,&nbsp;Kamran Javed Naquvi ,&nbsp;Md Faheem Haider ,&nbsp;Mohsin Ali Khan\",\"doi\":\"10.1016/j.ipha.2023.10.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Regulatory bodies are nowadays concerned with pharmaceutical drug products' safety, efficacy, and quality. Quality is the priority of all regulatory bodies, it is a high priority for the triple P factor (patient, pharmacist, and physician). It links pharmaceutical industries and regulatory authorities for designing, manufacturing, and consistently delivering safe and efficient products.</p><p>It mainly focuses on fabricating and designing formulations and manufacturing processes to ensure predefined product quality. It is based on the ICH Guidelines Q8 for pharmaceutical development, Q9 for quality risk management, and Q10 for pharmaceutical quality systems. Some of the important effective elements of QbD are to define the target profile that what is the requirement of the pharmacist, physician, and patient (TPP-QTPP) then measuring the criticality for achieving that target (CQA) and analyzing the risk assessment of variables associated with materials and controlling processes to produce consistent quality over time. The objective of this review is to discuss the concept of Quality by Design and describe its application in pharmaceutical product development.</p></div>\",\"PeriodicalId\":100682,\"journal\":{\"name\":\"Intelligent Pharmacy\",\"volume\":\"2 1\",\"pages\":\"Pages 122-129\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23000953/pdfft?md5=f841cf29030eede750e751b2b6ca7a7b&pid=1-s2.0-S2949866X23000953-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Intelligent Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23000953\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949866X23000953","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

如今,监管机构关注的是药品的安全性、有效性和质量。质量是所有监管机构的首要任务,也是三P因素(患者、药剂师和医生)的重中之重。它将制药业和监管机构联系在一起,以设计、生产和持续提供安全高效的产品。它主要侧重于配方和生产工艺的制造和设计,以确保预定的产品质量。它以 ICH 准则 Q8(药品开发)、Q9(质量风险管理)和 Q10(药品质量体系)为基础。QbD 的一些重要有效元素包括:定义药剂师、医生和患者要求的目标概况(TPP-QTPP),然后测量实现该目标的关键性(CQA),分析与材料和控制过程相关的变量的风险评估,以产生长期一致的质量。本综述旨在讨论 "质量源于设计 "的概念,并介绍其在医药产品开发中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Quality by design- newer technique for pharmaceutical product development

Regulatory bodies are nowadays concerned with pharmaceutical drug products' safety, efficacy, and quality. Quality is the priority of all regulatory bodies, it is a high priority for the triple P factor (patient, pharmacist, and physician). It links pharmaceutical industries and regulatory authorities for designing, manufacturing, and consistently delivering safe and efficient products.

It mainly focuses on fabricating and designing formulations and manufacturing processes to ensure predefined product quality. It is based on the ICH Guidelines Q8 for pharmaceutical development, Q9 for quality risk management, and Q10 for pharmaceutical quality systems. Some of the important effective elements of QbD are to define the target profile that what is the requirement of the pharmacist, physician, and patient (TPP-QTPP) then measuring the criticality for achieving that target (CQA) and analyzing the risk assessment of variables associated with materials and controlling processes to produce consistent quality over time. The objective of this review is to discuss the concept of Quality by Design and describe its application in pharmaceutical product development.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial Board Editorial Board Cardioprotective potential of Rosuvastatin against isoproterenol induced cardiac dysfunction and hypertrophy in the experimental model of rodents Sea buckthorn: A potential dietary supplement with multifaceted therapeutic activities Design of some potent non-toxic Autoimmune disorder inhibitors based on 2D-QSAR, CoMFA, molecular docking, and molecular dynamics investigations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1